Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea

Motoko Ida, Akito Nishida, Hiraku Akiho, Yoshihiro Nakashima, Kei Matsueda, Shin Fukudo, Motoko Ida, Akito Nishida, Hiraku Akiho, Yoshihiro Nakashima, Kei Matsueda, Shin Fukudo

Abstract

Background: Global assessment allows patients to assess improvement in multiple irritable bowel syndrome (IBS) symptoms. However, it was deemed important to assess "clinically meaningful improvements, focusing on the patient's chief complaint and the severity of major IBS symptoms" in addition to global assessment to show how ramosetron is effective for individual IBS symptoms. This is a pilot study to explore clinical endpoints focusing on the chief complaint of patients with IBS with diarrhea (IBS-D).

Methods: The same database was used in a previously reported post-marketing phase IV, randomized placebo-controlled pilot trial in male patients with IBS-D. The hypothesis is completely different from that of the other study. Patients with IBS-D diagnosed according to Rome III criteria were given either 5 μg of ramosetron (n = 47) or placebo (n = 51) once daily for 12 weeks after a one-week baseline period. To explore and examine endpoints that allow evaluation of "clinically meaningful improvements focusing on the patient's chief complaint," the chief complaint and its relief by this study drug were assessed in this exploratory study.

Results: Rates of patients with abdominal pain/discomfort, stool form and stool frequency which patients had as a chief complaint before administration were 34.0, 19.1 and 25.5%, respectively, in the ramosetron 5 μg group and 42.0, 18.0, and 20.0% in the placebo group. Responder rates for improvement in symptoms of the chief complaint that patients had before administration were 53.2% in the ramosetron 5 μg group and 42.0% in the placebo group at the last point. The greatest symptomatic improvement in the chief complaint in the ramosetron 5 μg group compared to the placebo group was shown with respect to stool consistency. Bristol Stool Form Scale (BSFS) scores were significantly lower in the ramosetron group than in the placebo group (4.36 ± 1.195 vs 4.85 ± 0.890 at the last point, P = 0.027) throughout the treatment period, except at week 6.

Conclusions: Ramosetron acted most effectively on stool consistency. Improvement in stool consistency is considered to be a clinically meaningful endpoint in showing how ramosetron was effective for individual IBS symptoms. (Clinicaltrials.gov ID: NCT00918411. Registered 9 June 2009).

Keywords: 5-hydroxytryptamine (5-HT); Abdominal discomfort; Abdominal pain; Global improvement; Stool consistency.

Figures

Fig. 1
Fig. 1
Improvement in symptoms of the chief complaint that patients had before administration of the study drug. a Improvement in symptoms of the chief complaint that patients had before administration of the study drug. b Responder rate for improvement in symptoms of the chief complaint that patients had before administration of the study drug. Height: responder rate (%). Error bar: 95% CI. P values were calculated using the χ2-test
Fig. 2
Fig. 2
Improvement in symptoms of each chief complaint that patients had before administration of the study drug
Fig. 3
Fig. 3
Weekly changes in BSFS scores. Line graph: means ± standard deviation. P values were calculated using the χ2-test, as follows: ***P < 0.001, **P < 0.01, and *P < 0.05
Fig. 4
Fig. 4
Monthly responder rates for improvement in stool consistency. Height: responder rate (%). Error bar: 95% CI. P values were calculated using the χ2-test as follows: ***P < 0.001, **P < 0.01, and *P < 0.05
Fig. 5
Fig. 5
Relationship between improvement in chief compliant and global assessment. Improvement in chief compliant that patients had before administration was compared between responders and non-responders for global assessment of relief of overall IBS symptoms

References

    1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377–90. doi: 10.1053/j.gastro.2006.03.008.
    1. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. 1990;99:409–15. doi: 10.1016/0016-5085(90)91023-Y.
    1. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–60. doi: 10.1053/gast.2000.16484.
    1. Saito YA, Talley NJ, Melton LJ, III, Fett S, Zinsmeister AR, Locke GR., III The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Neurogastroenterol Motil. 2003;15:687–94. doi: 10.1046/j.1350-1925.2003.00441.x.
    1. Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;21:663–76. doi: 10.1111/j.1365-2036.2005.02396.x.
    1. Kanazawa M, Miwa H, Nakagawa A, Kosako M, Akiho H, Fukudo S. Abdominal bloating is the most bothersome symptom in irritable bowel syndrome with constipation (IBS-C): a large population-based Internet survey in Japan. BioPyschoSoc Med. 2016;10:19. doi: 10.1186/s13030-016-0070-8.
    1. Miwa H. Prevalence of irritable bowel syndrome in Japan: Internet survey uing Rome III criteria. Patients Prefer Adherence. 2008;2:143–7.
    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. In: Drossman DA, Corazziari E, editors. Rome III. 3. McLean: Degnon Associates; 2006. pp. 487–509.
    1. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56:1770–98. doi: 10.1136/gut.2007.119446.
    1. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut. 1992;33:825–30. doi: 10.1136/gut.33.6.825.
    1. Kanazawa M, Palsson OS, Thiwan SI, Tumer MJ, van Tilburg MA, Gangarosa LM, et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol. 2008;103:2550–61. doi: 10.1111/j.1572-0241.2008.02066.x.
    1. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3:349–57. doi: 10.1016/S1542-3565(04)00726-8.
    1. Miyata K, Kamato T, Nishida A, Ito H, Katsuyama Y, Iwai A, et al. Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther. 1991;259:15–21.
    1. Miyata K, Kamato T, Nishida A, Ito H, Yuki H, Yamano M, et al. Role of the serotonin3 receptor in stress-induced defecation. J Pharmacol Exp Ther. 1992;261:297–303.
    1. Miyata K, Ito H, Fukudo S. Involvement of the 5-HT3 receptor in CRH-induced defecation in rats. Am J Physiol. 1998;274:G827–31.
    1. Miyata K, Yamano M, Kamato T, Akuzawa S. Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995;69:205–14. doi: 10.1254/jjp.69.205.
    1. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion. 2008;77:225–35. doi: 10.1159/000150632.
    1. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1202–11. doi: 10.1080/00365520802240255.
    1. Fukudo S, Matsueda K, Haruma K, Ida M, Hayase H, Akiho H, et al. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: a randomized, placebo-controlled phase II trial. Neurogastroenterol Motil. 2017
    1. Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150:358–66. doi: 10.1053/j.gastro.2015.10.047.
    1. Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, et al. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol. 2016;9:874–82. doi: 10.1007/s00535-016-1165-5.
    1. Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil. 2008;20:557–65. doi: 10.1111/j.1365-2982.2007.01069.x.
    1. Veldhuyzen van Zanten SJ, Talley NJ, et al. Design of treatment trial for the functional gastrointestinal disorders. In: Drossman DA et al., editors. Rome II –The functional gastrointestinal disorders. McLean: Degnon Associates; 2000. p. 577–622.
    1. Ida M, Nishida A, Akiho H, Nakashima Y, Matsueda K Fukudo S, Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea. BioPyschoSocial Medicine. 2017. doi:10.1186/s13030-017-0092-x.
    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91. doi: 10.1053/j.gastro.2005.11.061.
    1. Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014;12:953–9. doi: 10.1016/j.cgh.2013.11.024.
    1. Spiegel BM, Bolus R, Agarwal N, Sayuk G, Harris LA, Lucak S, et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther. 2010;32:1275–91. doi: 10.1111/j.1365-2036.2010.04464.x.
    1. Mangel AW, Northcutt AR. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther. 1999;13(Suppl. 2):77–82. doi: 10.1046/j.1365-2036.1999.00010.x.
    1. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-rating, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100:115–23. doi: 10.1111/j.1572-0241.2005.40365.x.
    1. O’Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ. 1990;300:439–40. doi: 10.1136/bmj.300.6722.439.
    1. Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura T, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50:11–30. doi: 10.1007/s00535-014-1017-0.
    1. Thompson WG, Heaton KW, Smyth GT, Symth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000;46:78–82. doi: 10.1136/gut.46.1.78.
    1. Koloski NA, Jones M, Kalantar J, Weltman M, Zaquirre J, Talley NJ. The brain-gut pathways in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61:1284–90. doi: 10.1136/gutjnl-2011-300474.
    1. Pimentel M, Talley NJ, Quigley EM, Hani A, Sharara A, Mahachai V. Report from the multinational irritable bowel syndrome initiative 2012. Gastroenterology. 2013
    1. Kux L. Department of Health and Human Services, Food and Drug Administration [docket no. FDA–2012–D–0146]: guidance for industry on irritable bowel syndrome—clinical evaluation of drugs for treatment: availability. Fed Regist. 2012;77:32124–5.
    1. Marquis P, Lasch KE, Delgado-Herrera L, Kothari S, Lembo A, Lademacher C, et al. Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome. Clin Transl Gastroenterol. 2014
    1. U.S. Department of Health and Human Services. Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims. 2009. .

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する